Search

Displaying results 4031 - 4040 of 10000 in total
  1. Drug

    Cimicoxib

    go.drugbank.com/drugs/DB05095
    Investigational

    If approved, Cimicoxib would be the first drug in decades to treat depression by a new mechanism of action. … Cimicoxib is a selective COX-2 inhibitor being developed by Affectis as a treatment for depression and schizophrenia.

  2. Drug

    Incadronic acid

    go.drugbank.com/drugs/DB06255
    Experimental

    [A14426,A14431,A14427,A202769] Incadronic acid was first described in the literature in 1991.[A202289] … Along with being investigated to treat hypercalcemia of malignancy,[A202862] it has also been investigated in the treatment of myeloma, leukemia, and other cancers.

    International brands: Yin Fu
  3. Drug

    Methyl 2,5-dihydroxycinnamate

    go.drugbank.com/drugs/DB16769
    Experimental

    Categories: Compounds used in a research, industrial, or household setting
  4. Drug

    Ergothioneine

    go.drugbank.com/drugs/DB17614
    Investigational

    Categories: Compounds used in a research, industrial, or household setting
  5. Drug

    Oltipraz

    go.drugbank.com/drugs/DB12539
    Investigational

    Oltipraz has been used in trials studying the treatment and prevention of Lung Cancer, Liver Fibrosis, Liver Cirrhosis, and Non-alcoholic Fatty Liver Disease.

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases. … LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development.

  7. Drug

    Morphine glucuronide

    go.drugbank.com/drugs/DB06409
    Investigational

  8. Drug

    Odanacatib

    go.drugbank.com/drugs/DB06670
    Investigational

    Odanacatib is an inhibiter of cathepsin K which was originally developed be Merck & Co as a new treatment for osteoporosis [A19388]. … The drug made it to phase III trials before abandoned due to increased stroke.

  9. Drug

    CEP-1347

    go.drugbank.com/drugs/DB05403
    Investigational

    CEP-1347 is a semi-synthetic compound shown to protect multiple nerve cell types from a variety of insults leading to programmed cell death (apoptosis) which could improve the survival of dopamine neurons

  10. Drug

    NXN-188

    go.drugbank.com/drugs/DB06096
    Investigational

    NXN-188 is a first-in-class, dual-action small molecule incorporating both neuronal nitric oxide synthase (nNOS) inhibition and 5-HT agonism that is being developed for the treatment of acute migraine.